23 and Everyone
By Atom Bergstrom
How do you finance universal genome and exosome testing on humans while simultaneously eliminating animal testing?
Develop an mRNA “vaccine” platform and a deep nasal swab to collect before-and-after results for bioengineering everyone on Earth into “transhuman resources” — the next step beyond “human resources.”
The “vaccine” is the secondary sleight of hand to take the attention off the primary data collection with the swab.
The digital dictatorship’s planetary data colonialism is designed to refashion humans into lab rats for eugenic objectives — 23 and Everyone — without (almost) anyone having a clue in a carload about this ubiquitous legerdemain.
The World Economic Forum is NOT governed from faraway Switzerland.
The Great Reset is straight out of Harvard in the good old U.S.A.
According to The Harvard Gazette (Oct. 1, 2019, yes, 2019) …
“Harvard University has established a multi-year research collaboration with the biotech company Moderna, Inc., with the goal of identifying and developing novel therapeutic approaches that could improve the lives of patients with immunological diseases. Additional funding from Moderna to Harvard Medical School (HMS) will establish an initiative at HMS called the Alliance for RNA Therapies for the Modulation of the Immune System (ARTiMIS), which will enable basic science research in the field of immunology using Moderna’s mRNA and nanoparticle delivery technology. The HMS Department of Immunology ihosted a symposium with Moderna to launch the ARTiMIS initiative last week.
“‘Between the ARTiMIS initiative and the broader research collaboration between Moderna and Harvard, we have established a collaborative framework to support continuous innovation in immunology,’ said Isaac Kohlberg, Harvard’s chief technology development officer and senior associate provost. ‘This access to focused funding and technical resources will enable Harvard researchers to make impactful advances in biomedical science, from the generation of basic biological insights to, we hope, the preclinical development of new immunotherapies.'”
According to the same source …
“To further advance insights toward therapeutics, Moderna has also entered into a multi-year research agreement with the university at large, through the Harvard Office of Technology Development. Under this collaboration framework, Moderna will initially provide sponsored research funding of up to $2.45 million in support of a project led by Ulrich von Andrian, the Edward Mallinckrodt Jr. Professor of Immunopathology and Director of the Center for Immune Imaging at HMS. This project aims to use mRNA technologies to study and manipulate the migration of immune cells from blood to tissues.”